Clinical Trial Update: Ruxolitinib in Thrombocythemia and Polycythemia Vera [Phase 2]

View source ↗

Summary

A Phase 2 trial of ruxolitinib for essential thrombocythemia and polycythemia vera is currently recruiting at Massachusetts General Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Polycythemia Vera

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Status: RECRUITING